Cancer Prevention and Screening – Hong Kong Perspective

Professor TH LAM
Chairman, Cancer Expert Working Group on Prevention and Screening
Chair Professor of Community Medicine, School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong

Symposium on “Cancer Control: Challenges & Opportunities”
7 December 2013
Outline

1. Coordinating Mechanism in Prevention and Control of Cancer
   a) Cancer Coordinating Committee
   b) Cancer Expert Working Group on Prevention and Control

2. 2012 CEWG Recommendations on Prevention and Screening of
   a) Breast Cancer
   b) Colorectal Cancer
   c) Prostate Cancer
Coordinating Mechanism in Prevention and Control of Cancer
Cancer Coordinating Committee

• Set up in 2001
• Chaired by Secretary for Food and Health
• To review local and international scientific evidence
• To formulate strategies and make recommendations for cancer prevention and control

• Under the Committee, four Cancer Expert Working Groups (CEWGs) has been set up:
  1. Cancer data and priorities
  2. Cancer prevention and screening
  3. Cancer treatment services standards
  4. Cancer research and development
Cancer Expert Working Group on Prevention and Screening

- Cancer Expert Working Group (CEWG) on Cancer Prevention and Screening was established in 2002
  - Review scientific evidence and provide local recommendations
  - Provide health advice on cancer prevention and screening for healthcare professionals and general public
Recommendations on Prevention and Screening

- Local recommendations for prevention and screening of seven cancers:
  1. Lung Cancer
  2. Colorectal Cancer
  3. Breast Cancer
  4. Liver Cancer
  5. Nasopharyngeal Cancer
  6. Cervical Cancer
  7. Prostate Cancer
Recommendations on Prevention and Screening

- CEWG released updated recommendations on the prevention and screening of 3 cancers, namely breast, colorectal, and prostate cancers in 2012.
- Three sets of cancer booklets in bilingual versions for general public were produced to promote public awareness and early detection.

- The recommendations and booklets are available at the following website: [http://www.chp.gov.hk/](http://www.chp.gov.hk/)
2012 CEWG Recommendations on Prevention and Screening for Breast Cancer
For ALL Females

- Be **breast aware** (being familiar with normal look, feel & cyclical changes of breasts so that unusual changes can be noticed)

- Breast awareness is different from offering training for BSE which is regular, formally taught and ritual self examination performed at the same time each month
For General Female Population

- Teaching women how to perform breast self-examination (e.g. at a monthly interval) is NOT recommended
- Insufficient evidence to recommend clinical breast examination
- Insufficient evidence to recommend for or against population-based mammography screening
## For Women at HIGH Risk

### Local Definition of high risk

<table>
<thead>
<tr>
<th></th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. <strong>Carrier of BRCA1/2 deleterious mutations</strong> confirmed by genetic testing</td>
<td>Women should see a doctor, and&lt;br&gt;• Have <strong>mammography screening</strong> every year;  &lt;br&gt;• Begin screening <strong>at age 35 or 10 years prior</strong> to the age at diagnosis of the youngest affected relative (for those with a family history), whichever is earlier, but not earlier than 30 years of age.</td>
</tr>
<tr>
<td>2. <strong>Family history of</strong>&lt;br&gt;a. <strong>Any 1º female relative</strong> being a confirmed carrier of BRCA1/2 deleterious mutations; &lt;br&gt;b. <strong>Any 1º or 2º female relative</strong> with both breast &amp; ovarian cancer (in the same person) regardless of age at diagnosis; &lt;br&gt;c. <strong>Any 1º female relative</strong> with bilateral breast cancer; &lt;br&gt;d. <strong>Any male relative</strong> with a history of breast cancer; &lt;br&gt;e. <strong>Two 1º female relatives</strong> diagnosed to have breast cancer AND one of them being diagnosed ≤ 50 years of age; &lt;br&gt;f. <strong>Two or more 1º or 2º female relatives</strong> with ovarian cancer regardless of age at diagnosis; &lt;br&gt;g. <strong>Three or more 1º or 2º female relatives</strong> with breast cancer OR a combination of breast cancer &amp; ovarian cancer, regardless of age at diagnosis.</td>
<td></td>
</tr>
<tr>
<td>3. <strong>Personal risk factors</strong>&lt;br&gt;a. History of radiation to chest for treatment (not Chest X-ray) between age 10 &amp; 30 years e.g. for Hodgkin’s disease; &lt;br&gt;b. History of breast cancer, including ductal carcinoma in situ (DCIS); &lt;br&gt;c. History of lobular carcinoma in situ (LCIS); &lt;br&gt;d. History of atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)</td>
<td>For <strong>confirmed carriers of BRCA1/2 deleterious mutations</strong> and women with radiation to chest for treatment between age 10 and 30 (e.g. for Hodgkin’s disease),&lt;br&gt;• Additional annual screening by <strong>supplementary MRI</strong> should be considered</td>
</tr>
</tbody>
</table>

* 1º female relatives include mother, daughter and sister <br>2º female relatives include grandmother, granddaughter, aunt, niece and half-sister
# For Women at Moderately Increased Risk

<table>
<thead>
<tr>
<th>Local Definition of moderately increased risk</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of</td>
<td>• Women should <strong>discuss with their doctors</strong> about the pros and cons of BC screening before deciding whether to start screening by <strong>mammography every two to three years</strong></td>
</tr>
<tr>
<td>a. <strong>Only 1° female relative</strong> with breast cancer diagnosed at or below 50 years of age; or</td>
<td>• <strong>MRI is not recommended</strong> for them</td>
</tr>
<tr>
<td>b. <strong>Two 1° female relatives</strong> diagnosed to have breast cancer after the age of 50</td>
<td></td>
</tr>
</tbody>
</table>
Genetic Testing

• Genetic testing should be performed by specialised centres with expertise in genetic counselling which should be provided before genetic testing

• Healthcare professionals should discuss with their clients about uncertainties and implications of tests results

<table>
<thead>
<tr>
<th>Target population:</th>
<th>Recommendations for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk due to family history</td>
<td>Genetic testing</td>
</tr>
<tr>
<td>• Women with any 1° female relative with confirmed BRCA1/2 deleterious mutations</td>
<td>• Genetic testing should be performed to confirm or refute their carrier status</td>
</tr>
<tr>
<td></td>
<td>• Confirmed carriers who wish to consider prophylactic surgery/chemoprevention should be referred to a specialist clinic for advice &amp; counselling</td>
</tr>
<tr>
<td></td>
<td>• Women at high risk due to family history other than having any 1° female relative with confirmed BRCA1/2 carrier status</td>
</tr>
<tr>
<td></td>
<td>• If they wish to clarify their genetic risk or that of their family, referral to a specialist clinic for advice, counselling and management should be discussed and considered</td>
</tr>
</tbody>
</table>
Primary Prevention for female breast cancer

• Primary prevention measures are important in lowering the risk of developing breast cancer

• Women are advised to:
  – Have regular physical activities
  – Avoid alcohol
  – Maintain a healthy body weight
  – Breastfeed each child for longer duration
  – Have childbirth at an earlier age

› Health promotion on breast cancer prevention should also be enhanced to raise the awareness of breast cancer in the public
Benefits and harms of population-based mammography screening

• **Mortality Reduction**
  – Overseas studies show controversial result: Ranging from 15-20% reduction to no mortality reduction with launching of screening programme
  – Impact on cancer mortality in Asian population is not available at the moment

• **False Positives**
  – Cochrane review (2011)\(^1\): 10 healthy women would be falsely labeled as having breast cancer and treated unnecessarily
  – Local modeling study (2008)\(^2\):
    • Local women aged 50-74 screened every 2 years
    • Result in 33,700 false positives per year

• **Over-diagnosis and treatment**
  – Cochrane review (2011) \(^1\): MMG leads to 30% over-diagnosis and over-treatment of BC
  – UK Panel on Breast Cancer Screening (2012)\(^3\): 3 over-diagnosed cases for every 1 breast cancer death prevented

Should Hong Kong introduce population-based MMG screening?

• **Local acceptance**
  – Population Health Survey (2003-2004)\(^4\): Only 13.3% of asymptomatic women aged ≥35 had mammography
  – Thematic Household Survey (2008)\(^5\): 24% of females in Hong Kong had mammogram during the past twelve months

• **Cost effectiveness**
  – Local modeling study (2010)\(^6\): MMG for HK Chinese women may not be cost-effective
  – Evaluate cost-effectiveness of mass MMG in HK (2012)\(^7\): Mass MMG screening of women aged 40-69 is the least cost-effective strategy compared with enhanced treatment and adjuvant therapy due to lower prevalence of breast cancer in HK

---

Should Hong Kong introduce population-based MMG screening?

- Consider different aspect of factors:
  - Age-standardised breast cancer incidence rate is rising in HK, but still much lower than those in Western countries
  - Performance of population-based MMG screening remains controversial in overseas countries (even those with much higher prevalence)
  - Harms, such as false positives and over-diagnosis may outweigh benefits
  - Positive predictive value of MMG (4.9%) would be lower than Western populations
    - generate harms related to unnecessary follow-up investigations
    - increase waiting time for symptomatic patients for further investigation and treatment
  - Low local acceptance of mammography
  - Local studies showed that population-based MMG screening may not be cost-effective

- Insufficient evidence for population-based MMG screening ➔ more local research and data are needed
Summary of 2012 CEWG Recommendations on Prevention and Screening of Breast Cancer

1. Currently, **insufficient evidence** to recommend for or against **population-based mammography screening** for women in Hong Kong.

2. When women consider mammography screening, healthcare professionals should discuss potential benefits and harms of screening with women so as to help them make an **informed decision**.

3. **Women at increased risk** should consult a doctor whether they should receive BC screening, starting age and frequency of screening.

4. All women should **be aware of breast changes** and visit doctors promptly if symptoms appear.

5. **Primary prevention measures** are important in lowering risk of developing breast cancer.
2012 CEWG Recommendations on Prevention and Screening for Colorectal Cancer
Recommendations on prevention and screening of Colorectal Cancer

• Territory-wide screening programme
  - Insufficient evidence to recommend for or against

• Informed screening for individuals aged 50-75 years
  - FOBT every 1 or 2 years; or
  - Flexible Sigmoidoscopy (FS) every 5 years; or
  - Colonoscopy every 10 years

• Superiority not yet determined
• Healthcare providers should discuss potential risks, benefits and limitations with clients to make informed choices
Recommendations on prevention and screening of Colorectal Cancer

Screening for high risk population

• Carriers of mutated gene of HNPCC
  ➢ Colonoscopy every 1-2 years from age 25

• Carriers of mutated gene of FAP
  ➢ FS every 2 years from age 12

• With one or more first degree relatives diagnosed to have CRC at or below 60 years of age
  ➢ Colonoscopy every 3-5 years from age 40 or 10 years prior to age of diagnosis of the youngest affected relative but not earlier than 12 years of age

• People whose family members are CRC patients with identifiable genetic mutations
  ➢ Two-tier screening by genetic testing and endoscopic examination
Recommendations on prevention and screening of Colorectal Cancer

- Primary prevention is very important in lowering the risk of having colorectal cancer.

- The public is advised to:
  - Increase intake of dietary fibre
  - Decrease consumption of red and processed meat
  - Increase physical activities
  - Maintaining healthy body weight
  - Avoid or quit tobacco smoking
  - Avoid alcohol drinking

- Health education on colorectal cancer prevention should be enhanced to raise the awareness of CRC in the public.
Local consideration for CRC screening

• Public acceptance
  – Population Health Survey (2003-2004)\textsuperscript{8}: 5.2% undertaken sigmoidoscopy or colonoscopy, 4.8% undertaken a FOBT
  – Cross-sectional population-based telephone survey conducted in (2007)\textsuperscript{9}:
    – Uptake rate of FOBT 12%
    – Uptake rate of colonoscopy 19%

• Capacity of healthcare system in HK
  – Population-based CRC screening programme will generate huge demand for screening, diagnostic and treatment services in public sector
  – Detailed planning and pilot testing are required before implementation of population-based CRC screening programme

• Cost-effectiveness of screening
  – Modeling study on cost-effectiveness of CRC screening tests in Asia (2008)\textsuperscript{10}: FOBT is the most cost-effectiveness screening method for CRC compared with no screening

\textsuperscript{8} Population Health Survey 2003-2004. Department of Health
\textsuperscript{9} So WK et al. (2012)
\textsuperscript{10} K.K.F. Tsoi et al. (2008)
Summary of 2012 CEWG Recommendations on Prevention and Screening for Colorectal Cancer

• Incidence of CRC is increasing in HK

• Primary preventive measures are important in prevention of CRC, namely lifestyle modification

• General public should be aware of symptoms of CRC and seek medical advice early

• Insufficient evidence to recommend for or against a territory wide screening programme

• Persons aged 50-75 should consider CRC screening either by annual or biennial FOBT, FS every 5 years or colonoscopy every 10 years

• Persons at high-risk of CRC should discuss with doctors to start CRC screening earlier and more frequently
2012 CEWG Recommendations on Prevention and Screening for Prostate Cancer
Recommendations on prevention and screening of prostate cancer

• Insufficient scientific evidence to recommend for or against screening for prostate cancer in men without any symptoms by PSA and/or DRE

• Asymptomatic men should discuss with their own doctor about their individual circumstances

• Make informed decision on whether or not to go for prostate cancer screening
Primary prevention of prostate cancer

- Effects of body weight, physical activity, and diet on prostate cancer risk are not clear
- Best advice about diet and activity to possibly reduce the risk of prostate cancer
  - Increase intake of dietary fibre
  - Decrease consumption of red and processed meat
  - Increase physical activities
  - Maintain healthy body weight
Screening tests of prostate cancer

- Performance of Digital Rectal Examination (DRE) and Serum Prostate Specific Antigen (PSA) in detecting prostate cancer\(^\text{11}\)

<table>
<thead>
<tr>
<th></th>
<th>sensitivity</th>
<th>specificity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRE</td>
<td>53.2% (range 49%-69.2%)</td>
<td>83.6% (range 18%-99.5%)</td>
<td>17.8% (range 5%-33.1%)</td>
</tr>
<tr>
<td>PSA at a cut-off level at 4ng/ml</td>
<td>72.1% (range 66.7%-100%)</td>
<td>93.2% (range 63.1%-100%)</td>
<td>25.1% (range 17%-57%)</td>
</tr>
</tbody>
</table>

Effectiveness of prostate cancer screening

- Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial\textsuperscript{12}
  - Annual screening (annual PSA testing for 6 years and DRE for 4 years) vs usual care (with opportunistic screening) as control group
  - After 13 years of follow-up, no evidence of mortality benefit for organised annual screening compared with opportunistic screening

<table>
<thead>
<tr>
<th></th>
<th>Incidence of prostate cancer</th>
<th>Death due to prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual screening group</td>
<td>108.4 per 10,000 person-years</td>
<td>3.7 per 10,000 person-years</td>
</tr>
<tr>
<td>Control group (40% received PSA screening in the 1\textsuperscript{st} year, increased to 52% in the 6\textsuperscript{th} year)</td>
<td>97.1 per 10,000 person-years</td>
<td>3.4 per 10,000 person-years</td>
</tr>
<tr>
<td>Relative risk</td>
<td>1.12 (95% CI 1.07-1.17)</td>
<td>1.09 (95% CI 0.87-1.36)</td>
</tr>
</tbody>
</table>

Effectiveness of prostate cancer screening

- European Randomized Study of Screening for Prostate Cancer (ERSPC)\textsuperscript{13}
  - PSA screening at an average of once every 4 years vs no screening as control

<table>
<thead>
<tr>
<th>Prostate Cancer</th>
<th>Incidence of prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA screening group</td>
<td>9.66 per 1,000 person-years</td>
</tr>
<tr>
<td>Control group</td>
<td>5.95 per 1,000 person-years</td>
</tr>
<tr>
<td>Relative risk</td>
<td>1.63 (95% CI 1.57-1.69)</td>
</tr>
</tbody>
</table>

- After a median follow-up of 11 years, PSA based screening for men 55-69 years of age reduced the rate of death from prostate cancer by 21% but did not affect all-cause mortality

<table>
<thead>
<tr>
<th>Death rate due to prostate cancer</th>
<th>Prostate Cancer</th>
<th>All causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA screening group</td>
<td>0.39 per 1,000 person-years</td>
<td>18.2 per 1,000 person-years</td>
</tr>
<tr>
<td>Control group</td>
<td>0.5 per 1,000 person-years</td>
<td>18.5 per 1,000 person-years</td>
</tr>
<tr>
<td>Relative risk</td>
<td>0.79 (95% CI 0.68-0.91)</td>
<td>0.99 (95% CI 0.97-1.01)</td>
</tr>
</tbody>
</table>

13. Fritz H. Schroeder, MD et al. (2012)
Local consideration for prostate cancer screening

- Effectiveness of prostate cancer screening uncertain because of lack of local RCT
- Lower prevalence of prostate cancer in HK – positive predictive value of DRE and PSA lower than Western countries
- May detect slow-growing prostate cancer that may not cause any symptoms or shorten life even if left untreated
- Subsequent investigations and treatment may cause anxiety and carry significant risks with little benefits
Summary of 2012 CEWG Recommendations on Prevention and Screening for Prostate Cancer

• Incidence of prostate cancer is increasing in HK but relatively low compared with some developed countries
• Primary preventive measures of prostate cancer are not well established
• Men should be aware of symptoms of prostate cancer and seek medical advice early
• Insufficient scientific evidence to recommend for or against screening for prostate cancer in men without any symptoms by PSA and/or DRE in HK
• Doctors should help men make an informed choice in a shared decision making process
Way Forward

• CEWG will keep in view new scientific evidence and updated overseas guidelines and review local recommendations as appropriate

• Health promotion on primary prevention of cancer should be enhanced
Acknowledgements

Co-chairman - Dr Ting-hung LEUNG

Members of CEWG:
• Dr Moon-tong CHEUNG
• Dr Kin-wah CHU
• Professor Sian GRIFFITHS
• Dr Linda Yin-fun HUI
• Dr Chun-key LAW
• Dr Roger NGAN Kai-cheong
• Ms Karen SADLER
• Dr Anthony Chi-ho YING
• Professor Ignatius Tak-sun YU

Secretary
• Dr Regina Cheuk-tuen CHING
Thank you